Clin2
NCT06456528Possibly a fitRecruiting

Study of QL0911 for low platelets caused by chemo

Cancer Treatment-Induced Thrombocytopenia

Part of Blood & lymphatic, Cancer clinical trials.

This trial tests a new drug called QL0911 to help raise platelet counts in people with cancer whose chemo has caused low platelets. The goal is to see if it can prevent delays in treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2/Phase 3
Enrollment
235 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have a confirmed cancer diagnosis and are on a 21-day chemotherapy cycle.
  • You have experienced low platelet counts (thrombocytopenia) that delayed your chemo.
  • You are able to do most of your daily activities (ECOG 0 or 1).
  • You do not have a history of bleeding problems or other blood disorders besides those caused by chemo.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07455006Not yet recruiting· Phase 3
Study of QL0911 for children with immune thrombocytopenia (ITP)

This trial tests if a new medicine called QL0911 can help children with chronic ITP who haven't improved with standard treatments. It aims to raise platelet counts and reduce bleeding risk.

NCT07286032Recruiting· Phase 3
Study of a pill to raise low platelets after chemo

This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.

Los Alamitos, California
NCT06440824Not yet recruiting· Phase 3
Testing a new platelet-boosting drug for treatment-resistant low platelets from cancer therapy

This trial tests a new drug called Romiplostim N01 to see if it works better than the standard treatment (recombinant human thrombopoietin) for raising low platelets caused by cancer therapies, when other treatments have failed. It is for people aged 18-75 with solid tumors or blood cancers who have not responded to at least two platelet growth factors.

NCT06759636Recruiting· Phase 3
Comparing two drugs for low platelets from cancer treatment

This trial tests if a new drug called Romiplostim N01 works better than the standard drug Interleukin-11 for raising low platelet counts caused by cancer treatments like chemotherapy or radiation. If you have low platelets from your cancer therapy, you may be able to join.

Nanjing, Jiangsu
NCT07185893Not yet recruiting
Study of a drug to raise low platelets during cancer treatment

This trial tests a medicine called Romiplostim N01 to help raise platelet levels in people with solid tumors who have low platelets from chemo, radiation, or immunotherapy. The goal is to see if it can safely improve platelet counts so patients can continue their cancer treatment.

Shijiazhuang, Hebei
NCT07408648Not yet recruiting· Phase 2
Testing a drug for low platelets from cancer treatment

This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.

Hear when a new Cancer Treatment-Induced Thrombocytopenia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.